| Index | — | P/E | 11.59 | EPS (ttm) | 1.95 | Insider Own | — | Shs Outstand | 532.22M | Perf Week | -0.62% |
| Market Cap | 12.03B | Forward P/E | 9.37 | EPS next Y | 2.41 | Insider Trans | — | Shs Float | 532.21M | Perf Month | 1.62% |
| Enterprise Value | 22.23B | PEG | 0.90 | EPS next Q | 0.73 | Short Float | 0.74% | Perf Quarter | -5.83% | ||
| Income | 1.09B | P/S | 0.53 | EPS this Y | 6.36% | Short Ratio | 4.91 | Perf Half Y | -0.18% | ||
| Sales | 22.66B | P/B | 0.78 | EPS next Y | 4.72% | ROA | 3.00% | Short Interest | 3.96M | Perf YTD | -5.08% |
| Book/sh | 29.02 | P/C | 7.28 | EPS next 5Y | 12.87% | ROE | 7.21% | 52W High | 26.95 -18.79% | Perf Year | -15.25% |
| Cash/sh | 3.11 | P/FCF | 5.84 | EPS past 3/5Y | 46.77% 4.87% | ROIC | 6.21% | 52W Low | 20.02 9.32% | Perf 3Y | 36.53% |
| Dividend Est. | 0.86 (3.95%) | EV/EBITDA | 5.56 | Sales past 3/5Y | 2.77% 1.69% | Gross Margin | 26.36% | Volatility | 1.35% 2.21% | Perf 5Y | -36.90% |
| Dividend TTM | 0.86 (3.95%) | EV/Sales | 0.98 | EPS Y/Y TTM | 97.05% | Oper. Margin | 10.69% | ATR (14) | 0.48 | Perf 10Y | -45.49% |
| Dividend Ex-Date | May 22, 2026 | Quick Ratio | 0.75 | Sales Y/Y TTM | 6.81% | Profit Margin | 4.83% | RSI (14) | 53.78 | Recom | 2.86 |
| Dividend Gr. 3/5Y | 4.74% 2.87% | Current Ratio | 1.07 | EPS Q/Q | 26.92% | SMA20 | 2.99% | Beta | 0.73 | Target Price | 24.50 |
| Payout | 0.00% | Debt/Eq | 0.77 | Sales Q/Q | 4.03% | SMA50 | 1.07% | Rel Volume | 1.56 | Prev Close | 22.61 |
| Employees | 108,165 | LT Debt/Eq | 0.64 | Earnings | Nov 03 | SMA200 | -1.17% | Avg Volume | 919.27K | Price | 21.89 |
| IPO Date | Sep 17, 1996 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 5.48% 0.59% | Net Debt/EBITDA | 2.55 | Volume | 1,432,288 | Change | -3.21% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Sep-29-26 | Reiterated | Berenberg Bank | $24 | |
| Aug-06-26 | Reiterated | Bernstein | Market Perform | $26 |
| Aug-05-26 | Reiterated | Truist Financial | Hold | $26 → $25 |
| Jul-28-26 | Reiterated | BNP Paribas | $20 | |
| Jan-20-26 | Downgrade | Goldman Sachs | Buy → Neutral | |
| Jan-05-26 | Reiterated | Truist Financial | Hold | $26 → $28 |
| Oct-15-25 | Downgrade | B of A Securities | Neutral → Underperform | |
| Sep-02-25 | Downgrade | UBS | Neutral → Sell | |
| May-15-24 | Reiterated | Truist Securities | Hold | $27 → $24 |
| Nov-24-23 | Upgrade | HSBC | Reduce → Hold |
Fresenius Medical Care AG & Co. KGaA specializes in comprehensive kidney dialysis treatment and associated services, operating across Germany, North America, and numerous international territories. Through an extensive network of outpatient clinics, it delivers essential dialysis therapy along with laboratory and diagnostic support. For home-based care, the company supplies necessary equipment, provides comprehensive training, and offers ongoing patient assistance, including clinical oversight and coordinating supply deliveries directly to patients. In the United States, Fresenius Medical Care also contracts with hospitals to provide vital dialysis interventions for hospitalized individuals suffering from end-stage renal disease (ESRD) and acute kidney failure. Beyond services, it is a prominent developer, manufacturer, and distributor of a broad range of dialysis products. This portfolio encompasses polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers and solutions, concentrates, bloodlines, renal pharmaceuticals, and water treatment systems. Additionally, the company produces non-dialysis medical devices, including acute cardiopulmonary and apheresis products. Its pharmaceutical division focuses on developing, acquiring, and in-licensing specialized renal medications, distributing these essential drugs and supplies to both individual patients' homes and dialysis centers. The company also extends its medical offerings to include a variety of specialized services such as vascular, cardiovascular, and endovascular care, operating ambulatory surgery centers for vascular procedures, and providing physician services in nephrology and cardiology. Products are sold directly to dialysis clinics, hospitals, and specialized treatment centers, complemented by sales through local teams, independent distributors, dealers, and agents. By February 23, 2022, Fresenius Medical Care managed an impressive network of 4,171 outpatient dialysis clinics across roughly 150 countries. Established in 1996, the company maintains its headquarters in Bad Homburg, Germany.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 22,662 | 22,143 | 20,919 | 21,042 | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 16,689 | 16,469 | 15,773 | 15,715 | — | — | — | — | — | |
| Gross Profit | 5,973 | 5,673 | 5,146 | 5,327 | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 3,471 | 3,421 | 3,400 | 3,457 | — | — | — | — | — | |
| Research and Development | 180 | 178 | 199 | 251 | — | — | — | — | — | |
| Other Operating Expense | 114 | 13 | -40 | 138 | — | — | — | — | — | |
| Operating Income | 2,207 | 2,061 | 1,588 | 1,481 | — | — | — | — | — | |
| Interest Expense | 446 | 434 | 440 | 459 | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | -9 | 79 | -4 | 95 | — | — | — | — | — | |
| Net Income Before Taxes | 1,751 | 1,706 | 1,143 | 1,117 | — | — | — | — | — | |
| Income Taxes | 366 | 362 | 342 | 325 | — | — | — | — | — | |
| Consolidated Net Income | 1,094 | 1,104 | 582 | 540 | — | — | — | — | — | |
| Net Income From Continuing Operations | 1,385 | 1,344 | 802 | 792 | — | — | — | — | — | |
| Net Income | 1,094 | 1,104 | 582 | 540 | — | — | — | — | — | |
| EPS (Recurring) | 1.95 | 1.90 | 1.00 | 0.92 | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 1.95 | 1.90 | 1.00 | 0.92 | — | — | — | — | — | |
| EPS (Diluted) | 1.95 | 1.90 | 1.00 | 0.92 | — | — | — | — | — | |
| EBITDA | 3,996 | 3,832 | 3,469 | 3,472 | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 11.22 | 12.57 | 22.75 | 22.66 | — | — | — | — | — | |
| Price To Sales Ratio | 0.52 | 0.63 | 0.64 | 0.58 | — | — | — | — | — | |
| Gross Margin | 26.36 | 25.62 | 24.60 | 25.32 | — | — | — | — | — | |
| Operating Margin | 9.74 | 9.31 | 7.59 | 7.04 | — | — | — | — | — | |
| Net Margin | 4.83 | 4.99 | 2.78 | 2.57 | — | — | — | — | — | |
| Shares Outstanding | 539 | 582 | 587 | 587 | — | — | — | — | — | |
| Market Capitalization | 11,796 | 13,863 | 13,290 | 12,227 | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |